PE20141146A1 - Inhibidores de la enzima activadora de nedd8 - Google Patents

Inhibidores de la enzima activadora de nedd8

Info

Publication number
PE20141146A1
PE20141146A1 PE2014000250A PE2014000250A PE20141146A1 PE 20141146 A1 PE20141146 A1 PE 20141146A1 PE 2014000250 A PE2014000250 A PE 2014000250A PE 2014000250 A PE2014000250 A PE 2014000250A PE 20141146 A1 PE20141146 A1 PE 20141146A1
Authority
PE
Peru
Prior art keywords
enzyme inhibitors
activating enzyme
nedd8 activating
refers
nedd8
Prior art date
Application number
PE2014000250A
Other languages
English (en)
Spanish (es)
Inventor
Ashley Sue Mccarron
Todd B Sells
Matthew Stirling
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of PE20141146A1 publication Critical patent/PE20141146A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2014000250A 2011-08-24 2012-08-23 Inhibidores de la enzima activadora de nedd8 PE20141146A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161526830P 2011-08-24 2011-08-24

Publications (1)

Publication Number Publication Date
PE20141146A1 true PE20141146A1 (es) 2014-09-21

Family

ID=47747080

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000250A PE20141146A1 (es) 2011-08-24 2012-08-23 Inhibidores de la enzima activadora de nedd8

Country Status (29)

Country Link
US (3) US8809356B2 (enExample)
EP (2) EP3323414A1 (enExample)
JP (1) JP6038150B2 (enExample)
KR (1) KR20140054288A (enExample)
CN (1) CN103889988B (enExample)
AR (1) AR087672A1 (enExample)
AU (1) AU2012298813B2 (enExample)
BR (1) BR112014004239A2 (enExample)
CA (1) CA2846231C (enExample)
CL (1) CL2014000441A1 (enExample)
CO (1) CO6900148A2 (enExample)
CR (1) CR20140128A (enExample)
DO (1) DOP2014000037A (enExample)
EA (1) EA031067B1 (enExample)
EC (1) ECSP14013263A (enExample)
GE (1) GEP201606522B (enExample)
HK (1) HK1199252A1 (enExample)
IL (1) IL231069B (enExample)
MA (1) MA35439B1 (enExample)
MX (1) MX2014002015A (enExample)
MY (1) MY166889A (enExample)
PE (1) PE20141146A1 (enExample)
PH (1) PH12014500419A1 (enExample)
SG (2) SG10201601023UA (enExample)
TN (1) TN2014000080A1 (enExample)
TW (1) TWI577667B (enExample)
UA (1) UA114894C2 (enExample)
UY (1) UY34292A (enExample)
WO (1) WO2013028832A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
GEP201606522B (en) * 2011-08-24 2016-08-10 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
EA035020B1 (ru) 2012-02-17 2020-04-17 Миллениум Фармасьютикалз, Инк. Пиразолопиримидиниловые ингибиторы убиквитин-активирующего фермента
US9593121B2 (en) 2012-08-03 2017-03-14 Millennium Pharmaceuticals, Inc. Indole substituted pyrrolopyrimidinyl inhibitors of Uba6
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
EA032577B1 (ru) * 2013-07-02 2019-06-28 Милленниум Фармасьютикалз, Инк. Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
TN2016000581A1 (en) 2014-07-01 2018-04-04 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of sumo activating enzyme
KR101927375B1 (ko) * 2016-04-20 2018-12-11 한국화학연구원 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2018213258A1 (en) * 2017-05-15 2018-11-22 Millennium Pharmaceuticals, Inc. Treatment of merlin-deficient tumors using nae inhibitors
LT3792260T (lt) 2018-05-08 2024-10-25 Nippon Shinyaku Co., Ltd. Azabenzimidazolo junginiai ir farmacinis preparatas
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
WO1997005132A1 (en) 1995-07-28 1997-02-13 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
AU2003291024A1 (en) 2002-11-13 2004-06-03 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
EP1758873A1 (en) 2004-06-22 2007-03-07 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
DK1848718T3 (da) 2005-02-04 2012-08-27 Millennium Pharm Inc E1 aktiveringsenzymhæmmere
BRPI0707493B8 (pt) 2006-02-02 2021-05-25 Millennium Pharm Inc composto inibidor de enzimas e1 ativadoras e composição farmacêutica contendo o referido composto
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
BRPI0715176A8 (pt) * 2006-08-08 2018-04-10 Millennium Pharm Inc compostos de heteroarila utéis como inibidores de enzimas de ativação e1
SG175929A1 (en) * 2009-05-14 2011-12-29 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
GEP201606522B (en) * 2011-08-24 2016-08-10 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
TR201807342T4 (tr) * 2011-11-03 2018-06-21 Millennium Pharm Inc NEDD8 aktive edici enzim inhibitörünün ve hipometile edici ajanın uygulanması.

Also Published As

Publication number Publication date
UA114894C2 (uk) 2017-08-28
US20180290983A1 (en) 2018-10-11
ECSP14013263A (es) 2014-04-30
MA35439B1 (fr) 2014-09-01
NZ622220A (en) 2016-04-29
CN103889988B (zh) 2018-05-04
EP2748168A4 (en) 2015-04-22
DOP2014000037A (es) 2014-04-15
US20130150388A1 (en) 2013-06-13
CA2846231C (en) 2017-06-20
AR087672A1 (es) 2014-04-09
SG11201400102WA (en) 2014-03-28
MX2014002015A (es) 2014-03-27
SG10201601023UA (en) 2016-03-30
US20150011572A1 (en) 2015-01-08
WO2013028832A3 (en) 2013-05-02
TWI577667B (zh) 2017-04-11
JP2014524476A (ja) 2014-09-22
AU2012298813A1 (en) 2013-05-02
HK1199252A1 (en) 2015-06-26
AU2012298813B2 (en) 2016-07-28
MY166889A (en) 2018-07-24
PH12014500419A1 (en) 2020-06-22
US9850214B2 (en) 2017-12-26
GEP201606522B (en) 2016-08-10
BR112014004239A2 (pt) 2017-03-21
EP3323414A1 (en) 2018-05-23
JP6038150B2 (ja) 2016-12-07
IL231069A0 (en) 2014-03-31
CR20140128A (es) 2014-05-15
CN103889988A (zh) 2014-06-25
UY34292A (es) 2013-04-05
CA2846231A1 (en) 2013-02-28
CO6900148A2 (es) 2014-03-20
EA201400249A1 (ru) 2014-05-30
CL2014000441A1 (es) 2014-09-26
KR20140054288A (ko) 2014-05-08
US8809356B2 (en) 2014-08-19
IL231069B (en) 2018-02-28
EP2748168A2 (en) 2014-07-02
TW201313689A (zh) 2013-04-01
WO2013028832A2 (en) 2013-02-28
TN2014000080A1 (en) 2015-07-01
EA031067B1 (ru) 2018-11-30

Similar Documents

Publication Publication Date Title
PE20141146A1 (es) Inhibidores de la enzima activadora de nedd8
BR112015006874A2 (pt) ligantes de rig-i inovadores e métodos para produzir os mesmos
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
BR112012006031A2 (pt) processo para preparação de compostos azabicíclicos.
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
NI201400032A (es) Piridopirazinas anticancerígenas via la
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
AR087451A1 (es) Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
EA202190619A1 (ru) Противовирусные соединения
EA201490396A1 (ru) Ингибиторы репликации вирусов гриппа
BR112014004219A2 (pt) pirano[3,2-d][1,3]tiazol como inibidores de glicosidase
BR112015021240A2 (pt) processo para sal de sódio de (2s, 5r)-2-carboxamido-7-oxo-6-sulfo-oxi-1,6-diaza-biciclo[3.2.1]octano
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
ECSP14013179A (es) Compuesto inhibidor de la señalización de la trayectoria notch
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
MX2012013206A (es) Inhibidores de quinasa biciclica fusionada.
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
EA201490756A1 (ru) Разагилина цитрамид
EA201391524A1 (ru) Производные гликозида и их применение
MX2013008699A (es) Compuestos para reducir la produccion de beta-amiloide.
EA201300647A1 (ru) Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц
MX2014004688A (es) Proceso de obtencion de acidos isoxazolil-metoxi-nicotinicos.

Legal Events

Date Code Title Description
FG Grant, registration